Review
Pharmacology & Pharmacy
Xiaowei Xie, Tianxiang Yue, Wenting Gu, Weiyi Cheng, Li He, Weiye Ren, Fanzhu Li, Ji-Gang Piao
Summary: This paper discusses the use of surface-functionalized mesoporous silica nanoparticles (MSN) as delivery vehicles for siRNA in cancer therapy. The advantages of using MSNs for siRNA loading and strategies to improve cellular uptake and endosomal escape are highlighted. Attention is also paid to the exciting progress made by combining RNAi with other therapies to improve cancer therapeutic outcomes.
Article
Biophysics
Anning Chen, Yaoheng Chen, Shixin Liu, Dong Ma, Jie Tang, Hongzheng Zhang
Summary: An amino-functionalized mesoporous silica nanoparticle-modified electrode array was developed for delivering siRNA-TGF81 into the inner ear to inhibit fibrosis after cochlear implantation. The results demonstrated that the nanoparticles had good siRNA loading capability and protective effect, and could be absorbed into the electrode arrays and work in the cochleae.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2022)
Article
Chemistry, Multidisciplinary
Qing Chang, Chenghao Liu, Zhiquan Xie, Qingfeng Shu, Yijun Xie, Qianqian Su, Xiaoyong Deng
Summary: In this study, a highly efficient nanocarrier for delivering siRNA into cancer cells was developed. The nanocarrier, made of fluorescent mesoporous silica nanoparticles with a polyethylenimine coating, showed good biocompatibility and negligible toxicity. By protecting siRNA from degradation, the nanocarrier successfully delivered siRNA into 293T cells and inhibited the expression of related genes. This study provides insights into the development of nonviral fluorescence nanocarriers for siRNA delivery, which is important for targeted cancer therapy.
Review
Biochemistry & Molecular Biology
Razieh Heidari, Vahideh Assadollahi, Pegah Khosravian, Seyed Abbas Mirzaei, Fatemeh Elahian
Summary: The use of nucleic acid to control gene expression is crucial in cancer research, and delivering nucleic acids using nanoparticles has emerged as a safe and efficient system for gene transfer.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Pharmacology & Pharmacy
Mohammed Elmowafy, Nabil K. Alruwaili, Naveed Ahmad, Abdulsalam M. Kassem, Mohamed F. Ibrahim
Summary: This study aimed to improve the physiochemical characteristics of poorly water-soluble quercetin (QT) by formulating it into lyophilized tablets using mesoporous silica nanoparticles (MSNPs) as carriers. The optimized formula showed a narrow particle size distribution, amorphous state, and enhanced dissolution rate and bioavailability.
Review
Pharmacology & Pharmacy
Eleen Dayana Mohamed Isa, Haslina Ahmad, Mohd Basyaruddin Abdul Rahman, Martin R. Gill
Summary: Mesoporous silica nanoparticles (MSNs) as drug delivery agents show great potential in cancer treatment by enhancing efficacy and reducing side effects. Through the development of smart DDAs and the capability to efficiently trap cargo molecules, MSNs have a bright future in both the diagnosis and treatment of cancer.
Review
Pharmacology & Pharmacy
Thashini Moodley, Moganavelli Singh
Summary: Cancer remains a devastating non-communicable disease with increasing incidence and mortality rates. The development of novel therapeutic strategies using multimodal nanotechnology is critical in enhancing therapeutic outcomes and overcoming resistance. Mesoporous silica nanoparticles have shown promising potential in cancer therapy with their stimuli-responsive controlled release functions and increased bioavailability.
Article
Biochemistry & Molecular Biology
Amelia Ultimo, Mar Orzaez, Maria J. Santos-Martinez, Ramon Martinez-Manez, Maria D. Marcos, Felix Sancenon, Eduardo Ruiz-Hernandez
Summary: The abnormal expression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium (RPE) is the main cause of subretinal neovascularisation in wet age-related macular degeneration (AMD). Encapsulating anti-VEGF drugs in large pore mesoporous silica nanoparticles (LP-MSNs) provides a potential solution for the issues in current AMD treatment, by improving drug penetration, retention time, and sustained release. In this study, an innovative LP-MSN-based nanosystem, functionalized with polyethylenimine (PEI) chains, is developed for topical administration of anti-VEGF siRNA molecules to RPE cells, demonstrating successful VEGF silencing.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, Research & Experimental
Saurabh Shah, Paras Famta, Deepkumar Bagasariya, Kondasingh Charankumar, Anupama Sikder, Rama Kashikar, Arun K. Kotha, Mahavir Bhupal Chougule, Dharmendra Kumar Khatri, Amit Asthana, Rajeev Singh Raghuvanshi, Shashi Bala Singh, Saurabh Srivastava
Summary: This review highlights the importance of mesoporous silica nanoparticles (MSN) as delivery vehicles in cancer therapy, including novel opportunities for biomimetic therapeutics and vaccine delivery. Parameters affecting MSN synthesis, drug loading characteristics, and targeting cancer cells specifically are explained. The applications and potential of MSN in nanotheranostics and imaging are illustrated. The review also discusses the hurdles encountered during the translation process and potential solutions.
MOLECULAR PHARMACEUTICS
(2022)
Review
Chemistry, Multidisciplinary
Blanca Escriche-Navarro, Andrea Escudero, Elena Lucena-Sanchez, Felix Sancenon, Alba Garcia-Fernandez, Ramon Martinez-Manez
Summary: Cancer immunotherapy has shown promise in treating various forms of cancer by stimulating the patient's immune system, but there are limitations to current treatments. The use of nanomaterials, particularly mesoporous silica nanoparticles (MSNs), has emerged as a potential tool to enhance cancer immunotherapy by improving efficacy and reducing side effects. This review explores the role of MSN and other nano/micro-materials in enhancing cancer immunotherapy and summarizes the different immunotherapeutic strategies addressed using MSN to date.
Article
Chemistry, Analytical
Albert Yu, Xiaoyong Dai, Zixian Wang, Huaqing Chen, Bing Guo, Laiqiang Huang
Summary: Immunotherapy is a promising treatment modality for cancer, using the body's immune response to fight against cancer. Mesoporous silica, as a nanomaterial, can facilitate the advancement of immunotherapy with its high porosity and biocompatibility.
Article
Chemistry, Multidisciplinary
Tianyu Li, Efrain E. Rodriguez
Summary: This study demonstrated the hydrothermal conversion of mesoporous TiO2 to mesoporous SrTiO3, with controlled pore size distribution and potential for high-temperature applications due to thermal stability.
CHEMICAL COMMUNICATIONS
(2022)
Article
Oncology
Shuchang Wang, Lulu Wo, Zizhen Zhang, Chunchao Zhu, Chaojie Wang, Yangyang Wang, Lechun Hou, Hui Cao, Qian Zhao, Enhao Zhao
Summary: In this study, the researchers found that LINC00589 was downregulated in gastric cancer patients and suppressed the metastatic ability of gastric cancer cells. Mechanistically, LINC00589 exerted its tumor suppressive function by promoting the degradation of hnRNPA1 protein. Furthermore, LINC00589 delivered by nanoparticles was able to effectively suppress peritoneal metastasis of gastric cancer.
Review
Chemistry, Multidisciplinary
Chun Xu, Chang Lei, Yue Wang, Chengzhong Yu
Summary: Dendritic mesoporous silica nanoparticles have attracted attention due to their wide applications, but the terminology used is ambiguous. This review provides a critical analysis of reported dendritic silica nanoparticles according to their structural classification, updating the understanding of their formation mechanisms and the control of structural parameters. The review also focuses on the applications of dendritic mesoporous nanoparticles in the biomedical field, offering new insights into the structure-property relationship.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2022)
Review
Chemistry, Multidisciplinary
Miguel Gisbert-Garzaran, Maria Vallet-Regi
Summary: Mesoporous silica nanoparticles are widely used in cancer treatment, with a focus on redox-responsive systems. This trend in design includes biological rationale, gatekeeper types, and nucleic acid scaffold nanoparticles.
Article
Chemistry, Multidisciplinary
Worapol Ngamcherdtrakul, Jingga Morry, Shenda Gu, David J. Castro, Shaun M. Goodyear, Thanapon Sangvanich, Moataz M. Reda, Richard Lee, Samuel A. Mihelic, Brandon L. Beckman, Zhi Hu, Joe W. Gray, Wassana Yantasee
ADVANCED FUNCTIONAL MATERIALS
(2015)
Article
Engineering, Biomedical
Jingga Morry, Worapol Ngamcherdtrakul, Shenda Gu, Shaun M. Goodyear, David J. Castro, Moataz M. Reda, Thanapon Sangvanich, Wassana Yantasee
Review
Oncology
Worapol Ngamcherdtrakul, David J. Castro, Shenda Gu, Jingga Morry, Moataz Reda, Joe W. Gray, Wassana Yantasee
CANCER TREATMENT REVIEWS
(2016)
Article
Oncology
Shenda Gu, Zhi Hu, Worapol Ngamcherdtrakul, David J. Castro, Jingga Morry, Moataz M. Reda, Joe W. Gray, Wassana Yantasee
Article
Oncology
Jingga Morry, Worapol Ngamcherdtrakul, Shenda Gu, Moataz Reda, David J. Castro, Thanapon Sangvanich, Joe W. Gray, Wassana Yantasee
MOLECULAR CANCER THERAPEUTICS
(2017)
Article
Multidisciplinary Sciences
Shenda Gu, Worapol Ngamcherdtrakul, Moataz Reda, Zhi Hu, Joe W. Gray, Wassana Yantasee
Review
Medicine, Research & Experimental
Mohamed Shehata Draz, Binbin Amanda Fang, Pengfei Zhang, Zhi Hu, Shenda Gu, Kevin C. Weng, Joe W. Gray, Fanqing Frank Chen
Article
Oncology
Moataz Reda, Worapol Ngamcherdtrakul, Shenda Gu, Daniel S. Bejan, Natnaree Siriwon, Joe W. Gray, Wassana Yantasee
Article
Chemistry, Multidisciplinary
Daniel S. Bejan, Sunil Sundalam, Haihong Jin, Rory K. Morgan, Ilsa T. Kirby, Ivan R. Siordia, Barr Tivon, Nir London, Michael S. Cohen
Summary: PARP16, a potential therapeutic target for cancer treatment, has poorly understood catalytic activity. This study describes the design of a selective PARP16 inhibitor and reveals that the catalytic activity of PARP16 regulates its solubility in response to nutrient stress.
Article
Biochemistry & Molecular Biology
Vinayak Palve, Claire E. Knezevic, Daniel S. Bejan, Yunting Luo, Xueli Li, Silvia Novakova, Eric A. Welsh, Bin Fang, Fumi Kinose, Eric B. Haura, Alvaro N. Monteiro, John M. Koomen, Michael S. Cohen, Harshani R. Lawrence, Uwe Rix
Summary: This study identifies the differential efficacy of multiple PARP inhibitors in small cell lung cancer cells. Talazoparib displays the highest potency and targets PARP16 in addition to PARP1. Silencing PARP16 significantly reduces cell survival, especially in combination with PARP1 inhibition.
CELL CHEMICAL BIOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Worapol Ngamcherdtrakul, Thanapon Sangvanich, Shaun Goodyear, Moataz Reda, Shenda Gu, David J. Castro, Primana Punnakitikashem, Wassana Yantasee
BIOENGINEERING-BASEL
(2019)
Article
Oncology
Zhi Hu, Jian-Hua Mao, Christina Curtis, Ge Huang, Shenda Gu, Laura Heiser, Marc E. Lenburg, James E. Korkola, Nora Bayani, Shamith Samarajiwa, Jose A. Seoane, Mark A. Dane, Amanda Esch, Heidi S. Feiler, Nicholas J. Wang, Mary Ann Hardwicke, Sylvie Laquerre, Jeff Jackson, Kenneth W. Wood, Barbara Weber, Paul T. Spellman, Samuel Aparicio, Richard Wooster, Carlos Caldas, Joe W. Gray
BREAST CANCER RESEARCH
(2016)